PAT Rs 79.70 Crore | Indegene Q4 FY26 Results

Indegene announced its Q4 FY26 financial results on April 29, 2026, reporting PAT of Rs 79.70 crore, a 32.2 percent year-on-year decline, as the Healthcare Technology and Life Sciences company delivered its January to March 2026 quarter earnings. Indegene Q4 FY26 results are closely tracked by investors as a key indicator of the company’s performance trajectory. This article covers the Indegene Q4 FY26 financial highlights, performance analysis, full year FY26 summary, management outlook, and frequently asked questions on Indegene Q4 results.

Indegene Q4 FY26 Financial Highlights

Indegene reported Q4 FY26 consolidated PAT of Rs 79.70 crore, a 32.2 percent year-on-year decline from Rs 117.60 crore in Q4 FY25. Revenue from operations surged 32.8 percent YoY to Rs 1,003.40 crore, crossing the Rs 1,000 crore quarterly revenue milestone for the first time. For FY26, PAT was Rs 401.10 crore on revenue of Rs 3,510.50 crore. EBITDA margin compressed to 16.3 percent from 19.5 percent as costs grew faster than revenue. The board recommended a final dividend of Rs 2.25 per share (up 12.5 percent YoY). The board recommended a dividend of Rs 2.25 per share for FY26.

Metric	Q4 FY26	Q4 FY25	YoY Change
Revenue / Total Income	Rs 1,003.40 crore	Refer NSE/BSE filing	Grew 32.8 percent YoY
PAT	Rs 79.70 crore	Refer NSE/BSE filing	Lower 32.2 percent YoY
Full Year FY26 PAT	Rs 401.10 crore (FY26 annual PAT)	Refer filing	As reported
Dividend (FY26)	Rs 2.25 per share	Refer filing	FY26 final

Also Read: Bhansali Engineering Polymers Q4 FY26 Results

Indegene Q4 FY26 Performance Analysis

Indegene Q4 FY26 revenue crossing Rs 1,000 crore for the first time is a milestone, driven by strong 32.8 percent YoY growth in healthcare technology, digital marketing, medical affairs, and regulatory services for top-20 global pharma companies. Indegene Q4 FY26 active client count reached 91, with 53 clients contributing over USD 1 million annually.

Indegene Q4 FY26 EBITDA margin contracted 320 basis points to 16.3 percent as employee costs and capability investments outpaced revenue growth. The cash conversion ratio of 162 percent in Indegene Q4 FY26 reflects strong underlying cash generation despite margin compression.

Indegene Full Year FY26 Business Summary

FY26 was a year of accelerated revenue growth for Indegene, with annual revenue growing 23.6 percent to Rs 3,510.50 crore. PAT was Rs 401.10 crore. The company has adopted GenAI across commercial, medical affairs, and regulatory operations, which is expected to improve margins in FY27.

Indegene Q4 FY26 Outlook and FY27 Priorities

Indegene FY27 priorities include restoring EBITDA margins toward 19-plus percent through operating leverage, growing the USD 1 million-plus client count beyond 53, and deepening GenAI integration across pharma client workflows globally.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces!

Conclusion

The Indegene Q4 FY26 results provide investors with the company’s January to March 2026 performance data. Indegene Q4 FY26 PAT of Rs 79.70 crore reflects the operational performance in the Healthcare Technology and Life Sciences sector. Investors tracking Indegene Q4 results should review the complete audited financials on NSE and BSE exchange filings before making any investment decision. Indegene Q4 FY26 is an important milestone in the company’s annual earnings calendar.

This article on Indegene Q4 FY26 results is for informational and educational purposes only. It is not investment advice. Please consult a SEBI registered investment advisor before making any investment decision. Past performance is not indicative of future results.

Frequently Asked Questions on Indegene Q4 FY26 Results

What were the Indegene Q4 FY26 results?

Indegene Q4 FY26 results were announced on April 29, 2026. The company reported PAT of Rs 79.70 crore for the January to March 2026 quarter. Indegene Q4 FY26 details are in the official NSE and BSE exchange filings.

What was Indegene Q4 FY26 PAT?

Indegene Q4 FY26 PAT was Rs 79.70 crore, lower 32.2 percent YoY. The Indegene Q4 FY26 results were announced on April 29, 2026, at the board of directors meeting to approve audited financials.

What was Indegene Q4 FY26 revenue?

Indegene Q4 FY26 revenue was Rs 1,003.40 crore. Investors should refer to the NSE and BSE exchange filing for the full audited Indegene Q4 FY26 revenue breakdown and segmental performance data.

Did Indegene declare a dividend after Q4 FY26 results?

Yes, Indegene declared a dividend of Rs 2.25 per share as part of the Q4 FY26 results announcement, subject to shareholder approval at the AGM.

What is the outlook for Indegene after Q4 FY26?

Indegene FY27 priorities include restoring EBITDA margins toward 19-plus percent through operating leverage, growing the USD 1 million-plus client count beyond 53, and deepening GenAI integration across pharma client workflows globally. Investors should monitor management commentary and quarterly filings for updated guidance on Indegene Q4 FY26 performance sustainability into FY27.

How did Indegene Q4 FY26 compare year on year?

Indegene Q4 FY26 PAT of Rs 79.70 crore was lower 32.2 percent YoY. The year-on-year comparison for Indegene Q4 FY26 versus Q4 FY25 is available in the official audited NSE and BSE exchange filings.

What sector does Indegene operate in?

Indegene operates in the Healthcare Technology and Life Sciences sector in India and is listed on NSE and BSE. Indegene Q4 FY26 results reflect the broader Healthcare Technology and Life Sciences sector trends for the January to March 2026 quarter. Contextualising Indegene Q4 performance within industry dynamics requires reviewing sector-level data alongside management commentary.

Is Indegene a good investment after Q4 FY26 results?

Whether Indegene is a good investment after the Indegene Q4 FY26 results depends on your individual financial goals, risk tolerance, and investment horizon. Indegene Q4 FY26 results provide one data point on the company’s trajectory. Always consult a SEBI registered financial advisor before making any investment decision.

Recent Article

Torrent Power Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Usha Martin Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Triveni Engineering and Industries Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Utkarsh Small Finance Bank Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Venus Pipes and Tubes Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook